Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00880360 · ClinicalTrials.gov registry record · Phase 2
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00880360 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 19 participants.
The verdict
NCT00880360, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.
Interventions
- DRUG Ontak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00880360
The ClinicalTrials.gov registry entry for NCT00880360 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ontak is the first listed.
NCT00880360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00880360 about?
NCT00880360 is a clinical study titled "A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer". This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.
What is the current status of trial NCT00880360?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2007-02. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00880360?
The interventions under investigation include: Ontak (DRUG).
Who is sponsoring clinical trial NCT00880360?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.